Physician profile
Erin E Kern
NPI 1407180441
$2,493.89
in general payments reported to CMS, 2019-2025
33 companies · $704 in 2025
The $704 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.78 · 2021: $250 · 2022: $500 · 2023: $283 · 2024: $661 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.81 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $237.27 | 2019-2025 | |
| Amgen INC. | $214.40 | 2022-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $202.48 | 2022-2025 | |
| Lilly USA, LLC | $201.97 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $146.84 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $106.66 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.05 | 2021-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.99 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $87.08 | 2022-2025 | |
| Dexcom, INC. | $84.14 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $82.06 | 2022-2024 | Freestyle Libre |
| Exact Sciences Corporation | $70.27 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $69.05 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $48.28 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $45.70 | 2023-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $45.48 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $44.51 | 2022-2024 | |
| Astellas Pharma US INC | $30.63 | 2023-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $25.97 | 2021 | |
| Chiesi USA, INC. | $22.47 | 2025 | Elfabrio |
| Merck Sharp & Dohme LLC | $21.16 | 2025 | Capvaxive |
| Abiomed | $20.92 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $20.17 | 2024 | Quviviq |
| Nestle Healthcare Nutrition INC. | $17.35 | 2023 | |
| Antares Pharma, INC. | $16.40 | 2022 | |
| Mylan Specialty L.P. | $16.24 | 2024 | Yupelri |
| Currax Pharmaceuticals LLC | $16.23 | 2022 | |
| Medtronic, INC. | $16.13 | 2022 | |
| Inspire Medical Systems, INC. | $16.13 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $14.09 | 2022 | |
| Eisai INC. | $11.88 | 2021 | |
| Genentech USA, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.